Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and TACE as Adjuvant Therapy for High-Risk Hepatocellular Carcinoma
NCT04213118Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2020
- Primary completion
- Feb 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in hepatocellular carcinoma (HCC), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Disease-Free Survival at 1 year. Status: unknown.
02
Drugs
anlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04213118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04213118.